Rivaroxaban 20mg daily vs Warfarin - major bleeding

RIVAROXABAN 20MG DAILY VS. WARFARIN (TO MAINTAIN AN INR OF 2-3), PATIENTS WITH NON VALVULAR AF, MAJOR BLEEDING

Study population:

Mean CHADS2 score 3.5

CHADS2 score > 3 (10%)

Median age 73 years (range 65-78)

Comments:

This means that treating 200 patients with rivaroxaban instead of warfarin for 1.9 years might prevent one stroke or systemic embolism, and treating 250 patients with rivaroxaban instead of warfarin for 1.9 years might cause one major bleeding episode. Note, however, that the warfarin group were within therapeutic range only 55% of the time.

NNH, with respect to major bleeding, 260 (in favour of warfarin)